MIF-1 can accelerate neuromotor, EEG and behavioral development in mice
Related Experiment Videos
A d'Amore1, S Pieretti, S Palazzesi
1Istituto Superiore di Sanità, Roma, Italy.
Insights
This study shows that macrophage migration inhibitory factor-1 (MIF-1) given to newborn mice accelerated neurological, physical, and brainwave development. These improvements persisted into adulthood, enhancing maze learning abilities.
Area of Science:
- Neuroscience
- Developmental Biology
- Pharmacology
Background:
- Early-life development is crucial for long-term health and cognitive function.
- Macrophage migration inhibitory factor-1 (MIF-1) is a cytokine with potential roles in development.
- Understanding factors that influence neurodevelopment is essential for identifying therapeutic targets.
Purpose of the Study:
- To investigate the effects of early-life administration of MIF-1 on neurodevelopment and behavior in mice.
- To determine if MIF-1 treatment influences physical growth, neurological reflexes, and electroencephalographic activity.
- To assess the long-term impact of neonatal MIF-1 exposure on learning abilities in adulthood.
Main Methods:
- Newborn mice received daily subcutaneous injections of MIF-1 (1 mg/kg) or saline for the first 19 days of life.
- Physical (body weight, eye/ear opening), neurobehavioral (reflexes), and neurophysiological (EEG) parameters were monitored until weaning.
- Maze learning task performance was evaluated in early adulthood (40 days of age).
Main Results:
- MIF-1 treatment significantly accelerated neurological development (days 3-9).
- Somatic (days 10-14) and electroencephalographic (days 16-19) development were also enhanced by MIF-1.
- Mice treated with MIF-1 exhibited improved learning abilities in an appetitive maze task in early adulthood.
Conclusions:
- Neonatal administration of MIF-1 promotes accelerated neurodevelopment and somatic growth in mice.
- The beneficial effects of early-life MIF-1 exposure extend into adulthood, enhancing cognitive functions like learning.
- MIF-1 represents a potential therapeutic agent for modulating early-life development and improving cognitive outcomes.
Abstract:
Newborn mice were injected SC daily with 1 mg/kg of MIF-1 or saline during the first 19 days of life. The progress of each pup was monitored for physical (body weight, eye and ear opening), neurobehavioral (reflexes) and neurophysiological (EEG) development until the weaning stage. In early adulthood (40 days of age) mice were tested on a maze learning task. Results indicate that MIF-1 can accelerate neurologic (days 3-9), somatic (days 10-14) and electroencephalographic (days 16-19) parameters, and that the effects of treatment last into the early adult stage with increased learning abilities in an appetitive task.